
AAN.COM(HTTPS://WWW.AAN.COM/)



Advertisement





April 05, 2016; 86 (16 Supplement) APRIL 16, 2016

Nicotinamide: A Key Player in the Developmental Origins of Parkinson's Disease? (I1.001)

Adrian Williams, Síle Griffin, Mark Pickard, Rosemary Fricker First published April 4, 2016,

66 CITATION	₽ PERMISSIONS
MAKE COMMENT	⇒ SEE COMMENTS



Downloads 0

SHARE

▼ f **У** in

Article

Info & Disclosures

Abstract

OBJECTIVE: To investigate the role of vitamin B₃ (nicotinamide) on midbrain dopaminergic neuron development. BACKGROUND: The active forms of vitamins A & C are linked to optimal development of neurons. Little is known regarding the role of vitamin B3 even though poor cognitive development and parkinsonism were features of pellagra. **DESIGN/METHODS:** Monolayer mouse embryonic stem cell cultures (mESC; Sox1GFP knock-in 46C cell line) were treated with nicotinamide for different durations and immunocytochemistry/ fluorescence microscopy was performed to assess the expression of stem cell, neural progenitor (NP) and neuronal subtype markers. RESULTS: Nicotinamide accelerated the conversion process of mESCs to neurons with a catecholaminergic phenotype. Specifically, the proportion of proliferating cells was significantly reduced in nicotinamidetreated cultures - that is, nicotinamide regulates the proliferation-to-differentiation switch from NPs to neurons during development. Nicotinamide drives dopamine neuron differentiation (10mM) as effectively as known cocktails of signalling factors, and acts in a dose-dependent manner in a defined time-window - with high doses (20mM) however causing toxicity. CONCLUSIONS: Nicotinamide aids the conversion of stem cells to dopaminergic neurons increasing efficiency and safety of the cells produced, and reducing cost; important as we progress towards patient-specific cell replacement therapy for Parkinson's . Our data also suggest that nicotinamide is a key signalling factor required in a definable dosage range at key times for the formation of a healthy population of dopamine neurons. An optimal maternal to foetal dietary dosage of nicotinamide - neither too low nor too high - could be linked to Parkinson's disease later in life.

Disclosure: Dr. Williams has nothing to disclose. Dr. Griffin has nothing to disclose. Dr. Pickard has nothing to disclose. Dr. Fricker has nothing to disclose.

Saturday, April 16 2016, 1:00 pm-5:30 pm

Copyright © 2016 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.

● COMMENT

YOU MAY ALSO BE INTERESTED IN

APRIL 21, 2016

Nicotinamide: A Key Player in the Developmental Origins of Parkinson's Disease? (P6.386) Adrian Williams, Síle Griffin, Mark Pickard, et al.

April 04, 2016

CLINICAL IMPLICATIONS OF NEUROSCIENCE RESEARCH

DNA damage response Selected review and neurologic implications

Elizabeth A. Coon, Eduardo E. Benarroch January 19, 2018

▲ Back to top

Advertisement

RELATED ARTICLES

No related articles found.

ALERT ME

Alert me when eletters are published



Articles

Ahead of Print

Current Issue

Past Issues

Popular Articles

Translations

About

About the Journals

Ethics Policies

Editors & Editorial Board

Contact Us

Advertise

Submit

Author Center

Submit a Manuscript

Information for Reviewers

AAN Guidelines

Permissions

Subscribers

Subscribe

Activate a Subscription

Sign up for eAlerts

RSS Feed







Neurology

Neurology: Clinical Practice

Neurology: Genetics

Neurology: Neuroimmunology & Neuroinflammation

AAN.com

AANnews

Continuum

Brain & Life

Neurology Today





Neurology | Print ISSN:0028-3878 Online ISSN:1526-632X © 2021 American Academy of Neurology

Privacy Policy Feedback Advertise